Anti-cancer n-terminal fc conjugated immunotherapeutics
AssigneeImmunofyx
InventorMark WILLIAMS
Life of this patent
Estimating the term…
Abstract
Compounds for the prevention and treatment of cancer have a first binding peptide from a urokinase-type plasminogen receptor (uPAR) antagonist operatively linked to an antibody peptide operatively linked to a second binding peptide from an endostatin or plasminogen derived peptide sequence.
Claims27
A compound comprising:
- a first binding peptide from a urokinase-type plasminogen receptor (uPAR) antagonist having activity of a uPAR antangonist, operatively linked to a N-terminal of an immunoglobulin G (IgG) antibody peptide operatively linked to
- a C-terminal of the immunoglobulin G (IgG) antibody peptide operatively linked to a second binding peptide from an endostatin derived peptide sequence having endostatin activity or plasminogen derived peptide sequence having plasminogen activity.
(canceled)
(canceled)
(canceled)
(canceled)
A compound comprising a compound at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the peptide coded by a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, and SEQ ID No. 13.
A compound selected from the group consisting of G-Fc-Endostatin (P125A), ATN658-Fc-K5, Herceptin-Fc-ATF, Avastin-Fc-ATF, Human IgG1 Fc-linker-ATF, ATF-Linker-hIgG4 Fc-Kringle domain K5, ATF-Linker-hIgG4 Fc-Endostatin (P125A), ATF-Linker-hIgG4 Fc-Endostatin (P125A), Herceptin-Fc-K5, ATF-Fc (IgG4)-linker-Kringle Domains 1-3, Herceptin-Arrestin, ATF-huIgG4 Fc-Arrestin and ATN658-Endostatin (P125).
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.